期刊文献+

铜绿假单胞菌的耐药性及碳青霉烯类抗生素的研究进展 被引量:6

Progress in research on drug-resistance of Pseudomonas aeruginosa and carbapenem antibiotics
暂未订购
导出
摘要 铜绿假单胞菌(Pseudomonas aeruginosa)是一种常见的医院内获得性感染致病菌,其耐药性强,耐药谱广。亚胺培南等碳青霉烯类抗生素是近年来治疗铜绿假单胞菌疗效较好的药物,但随着临床的广泛应用,铜绿假单胞菌对亚胺培南等产生了耐药性。铜绿假单胞菌对碳青霉烯类抗生素的耐药机制有β-内酰胺酶的水解、外膜通透性降低和主动外排系统的排出等,这些耐药机制之间相互协同作用而产生高度耐药。针对这些耐药机制,开发活性更高、安全性更好的碳青霉烯类抗生素显得极为迫切。本文对铜绿假单胞菌的耐药性及碳青霉烯类抗生素的研究进展进行了综述。 Pseudomonas aeruginosa is a primary pathogen in nosocomial infections. Its antibiotic-resistance is strong and resistance spectrum is broad. Carbapenem antibiotics like imipenem are illustrious antibiotics in the treatment of Pseudomonas aeruginosa infection in recent years. With wide use of carbapenem antibiotics in the treatment of bacterial infection, P. aeruginosa has become resistant to carbapenem antibiotics. The resistance mechanisms of P. aeruginosa to carbapenem antibiotics are hydrolysis of carbapenem by beta-lactamase, decrease in drug penetration of baderial outer membrane, ejection by efflux pump and so on. According to these resistance mechanisms, it is urgent to develop new agents with higher activity, sefety and efficacy. In this paper, the research progress of resistance of P. aeruginosa and carbapenem antibiotics in recent years are briefly reviewed.
作者 牛秀明 官波
出处 《国外医学(药学分册)》 2007年第3期194-199,共6页 Foreign Medical Sciences(Section of Pharmarcy)
关键词 铜绿假单胞菌 耐药机制 碳青霉烯 Pseudomonas aeruginosa resistance mechanism carbapenem antibiotics
  • 相关文献

参考文献24

  • 1Pournaras S,Maniati M,Petinaki E,et al.Hospital outbreak of multiple clones of Pseudomonas aeruginosa carrying the unrelated metallo-beta-lactamase gene variants blaVIM-2 and blaVIM-4[J].JAntimicrob Chemother,2003,51(6):1409-1414.
  • 2Cavallo JD,Leblanc F,Fabre R.Surveillance of Pseudomonas aeruginosa sensitivity to antibiotics in France and distribution of beta-lactam resistance mechanisms:1998 GERPB study[J].Pathol Biol(Paris),2000,48(5):472-477.
  • 3Bantar C,Famiglietti A,Goldberg M,et al.Three-year surveillance study of nosocomial bacterial resistance in Argentina[J].Int J Infect Dis,2000,4(2):85-90.
  • 4Crespo MP,Woodford N,Sinclair A,et al.Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8,a novel metallo-beta-lactamase,in a tertiary care center in Cali,Colombia[J].J Clin Microbiol,2004,42(11):5094-5101.
  • 5Gladstone P,Rajendran P,Brahmadathan KN.Incidence of carbapenem resistant nonfermenting gram-negative bacilli from patients with respiratory infections in the intensive care units[J].Indian J Med Microbial,2005,23(3):189-191.
  • 6朱德妹,汪复,张婴元.2004年上海地区细菌耐药性监测[J].中国抗感染化疗杂志,2005,5(4):195-200. 被引量:227
  • 7Cardoso O,Sousa JC,Leitao R,et al.Carbapenem-hydmlysing beta-lactamase from clinical isolates of Pseudomonas aeruginose in Portugal[J].J Antimicrob Chemother,1999,44(1):135-138.
  • 8Tsakris A,Poumaras S,Woodfold N,et al.Outbreak of infections caused by Psendomonas aeruginosa producing VIM-1 carbapenemase in Greece[J].J Clin Microbiol,2000,38(3):1290-1292.
  • 9Nikaido H.Prevention of drug access to bacterial targets:permeability barriers and active efflux[J].Science,1994,264(5157):382-388.
  • 10Suller MT,Russell AD.Triclosan and antibiotic resistance in Staphylococcus aureus[J].J Antimicrob Chemother,2000,46(1):11-18.

二级参考文献41

  • 1朱德妹,汪复,胡付品,吴湜,张婴元.2002年上海地区医院细菌耐药性监测[J].中华传染病杂志,2004,22(3):154-159. 被引量:63
  • 2朱德妹,汪复,张婴元.2003年上海地区细菌耐药性监测[J].中国抗感染化疗杂志,2005,5(1):4-12. 被引量:147
  • 3吴永乐.新的碳青霉烯类抗生素[J].国外医药(抗生素分册),1995,16(3):178-182. 被引量:8
  • 4Kahan J S. Kahan F M, Goegelman R, el al. Thienamycin, a new beta-lacram anlibiotic: 1. Discovery. taxonomy, isolation and physical properties [J]. ,J Amibiol.1979.32(1 ):1.
  • 5Kahan F M, Kropp H, Sundelof J G, et al. Thienamycin: Development of imipenem-cilastatin [J]. J Antimicrob Chemother, 1983,12 (Suppl D) : 1.
  • 6Peterson P J, Jacobus N V, Weiss W J, et al. In vitro and in vivo activities of LJC 10.627, a new carbapenem with stability to dehydropeptidase [J]. Antimicrob Agents Chemother, 1991,35(1 ) :203.
  • 7Jacoby G, Han P, Tran J. Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multirisistant Gram-negative clinical pathogens [J]. Antimicrob Agents Chemother, 1997,41 (8) : 1830.
  • 8Fuchs P C, Barry A L, Brown S D. et al. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 north American medical centers [J]. Antirnicrob Agents Cherm~ther, 2001,45 ( 6 ) : 1915.
  • 9Rosen H, Hajdu R, Silver 1., et al. Reduced immunotoxicity and preservation of anlibacterial activity in a releasable side-chain carbapenem antibiotic [J]. Science. 1999.283:70.3.
  • 10Sorbera L A, Rabsseda J, Castaner P A, et al. MK-0826 [J]. Drugs Fut,2000,25(8):795.

共引文献240

同被引文献51

引证文献6

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部